文献速递乳腺PETMR

专用乳腺PET对BI-RADS 4类乳腺病变的评估价值

Dedicated breast PET value to evaluate BI-RADS 4 breast lesions.
PubMed 文献 · Eur J Radiol · 2018-10-02

前瞻性纳入50例女性60个BI-RADS 4类乳腺病变,活检前均行MRI和专用乳腺PET(dbPET)并行图像融合定位,与组织病理对照。dbPET诊断恶性的敏感度50%、特异度76%,原位癌假阴性率85.7%,作者据此不推荐dbPET用于BI-RADS 4类病变的恶性诊断,但病变大于0.1 cm且位于视野内时dbPET显示了全部浸润性癌。

要点

  • dbPET诊断BI-RADS 4类病变恶性的敏感度50%、特异度76%。
  • dbPET对原位癌检出假阴性率85.7%,是主要局限。
  • 病变大于0.1 cm且位于视野内时,dbPET显示了全部浸润性癌。

核心结论

  • 作者认为其分析不支持将dbPET用于乳腺X线或超声发现的BI-RADS 4类病变的恶性诊断,主要因dbPET对原位癌检出假阴性率高(85.7%)。
  • 作者指出,病变大于0.1 cm且位于视野内时,dbPET显示了全部浸润性癌。

研究设计与样本

  • 前瞻性研究,经机构审查委员会和患者批准,连续纳入50例女性60个BI-RADS 4类乳腺病变。
  • 所有患者活检前均行MRI和dbPET,并将MRI与dbPET图像融合以更好地定位相应病变。
  • 最终影像所见与组织病理结果对照,计算dbPET的敏感度、特异度及其95%置信区间。

关键影像表现/征象

  • 组织病理显示18个恶性病变(7个原位癌、11个浸润性癌)和42个良性病变。
  • dbPET报告41例无恶性证据,其中9例组织学诊断为肿瘤。
  • dbPET显示10个良性病变和9个乳腺癌代谢活性增高。
  • 2个浸润性癌距胸肌小于1 cm,因位于视野外被dbPET漏诊。
  • 另有6个假阴性结果,对应1个0.1 cm浸润性小叶癌和5个原位癌。

诊断标准与关键数值

  • dbPET诊断恶性的敏感度为50%,特异度为76%,敏感度和特异度均给出各自的95%置信区间。
  • dbPET对原位癌检出的假阴性率为85.7%。

临床应用与阅片要点

  • 作者认为其分析不支持将dbPET用于乳腺X线或超声发现的BI-RADS 4类病变的恶性诊断。
  • 作者指出,病变大于0.1 cm且位于视野内时,dbPET显示了全部浸润性癌。
  • 距胸肌小于1 cm的病变可因位于dbPET视野外而被漏诊。

局限性

  • 作者结论指出其分析不支持推荐dbPET用于BI-RADS 4类病变诊断,主要因对原位癌检出假阴性率高(85.7%)。
  • 距胸肌小于1 cm的浸润性癌因位于dbPET视野外而被漏诊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the diagnostic value of dedicated breast PET (dbPET) parallel imaging in mammographically or sonographically detected BI-RADS 4 (Breast Imaging Reporting And Data Systems) lesions.

MATERIALS AND METHODS: After institutional review board and patient approvals, 50 consecutive women with 60 BI-RADS 4 breast lesions were prospectively included in the study. All patients underwent Magnetic Resonance Imaging (MRI) and dbPET before biopsy and fusion of both MRI and dbPET images was performed to better locate corresponding lesions. Final findings were compared with histological results. Sensitivity and specificity for dbPET were determined along with their respective 95%-confidence intervals.

RESULTS: Histopathology examination revealed 18 malignant lesions (7 in situ and 11 invasive carcinomas) and 42 benign entities. The dedicated breast PET reported no evidence of malignancy in 41 patients, 9 of them with histological diagnosis of neoplasm. Besides, dbPET showed increased metabolically activity in 10 benign lesions and in 9 breast cancers. Two invasive carcinomas were located less than 1 cm from the pectoral muscle, which can explain that they were missed by dbPET because they were outside the field of view (FOV). There were other 6 false negative results, which corresponded to a 0.1 cm invasive lobular carcinoma and 5 in situ carcinomas. Sensitivity and specificity of dbPET were 50% and 76%, respectively.

CONCLUSIONS: Our analysis does not allow the recommendation of dbPET for diagnosis of malignancy in BI-RADS 4 mammographic or US abnormalities, mainly due to its high false-negative rate for the detection of in situ carcinomas (85.7%). However, considering the lesions greater than 0.1 cm and included in the FOV, dbPET depicted all invasive carcinomas.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Graña-López L, Herranz M, Domínguez-Prado I, et al. Dedicated breast PET value to evaluate BI-RADS 4 breast lesions. Eur J Radiol. 2018. PMID: 30396656. doi:10.1016/j.ejrad.2018.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。